Oxford BioDynamics Plc (OXBOF)

Revenue by Product

Financials in millions GBX. Fiscal year is October - September.

Year Ending	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018	Sep 30, 2017
Proprietary Products	408.00K
Proprietary Products Growth	110.31%
Biomarker Research and Development	228.00K
Biomarker Research and Development Growth	-27.85%

Revenue by Geography

Financials in millions GBX. Fiscal year is October - September.

Year Ending	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018	Sep 30, 2017
United States	459.00K
United States Growth	18.30%
Rest of World	177.00K
Rest of World Growth	45.08%